Pipeline
 |
 |
 |
BB3 (HGF mimetic) |
Renal transplantation (acute) |
 |
Myocardial infarction (acute) |
|
|
Hepatic fibrosis (chronic) |
|
|
 |
||
ANG-2684, ANG-3038 (PARP inhibitor) |
Acute pancreatitis Stroke |
|
|
||
ANG-3067 (retinoic acid signaling modulator) |
Fibrosis |
|
|
||
ANG-3407 (CYP17 inhibitor) |
Prostate cancer |
|
|
||
ANG-3070 (Kinase inhibitor) |
Chronic kidney disease Scleroderma |
|
|
||
ANG-4011 (Relaxin mimetic) |
Chronic kidney disease |
|
Market Opportunities
The size of target markets for Angion’s compounds is summarized in the following tables.
US market size for HGF/SF mimetics
| Disease | Indication | Prevalence | Incidence |
Cardiovascular disease |
Myocardial infarction |
|
2,000,000(1) |
Atherosclerosis |
5,100,000 |
|
|
Liver fibrosis |
Fibrosis secondary to HCV Chronic infection |
4,000,000 |
|
Kidney injury |
Contrast medium nephropathy |
|
2,000,000(1) |
Spinal cord injury |
Contusive spinal cord injury |
250,000 |
12,000 |
Fulminant liver failure |
Fulminant liver failure |
|
1,000 |
Lung fibrosis |
Idiopathic lung fibrosis, drug-induced fibrosis |
200,000 |
|
(1) The patient population with myocardial infarction undergoing angiography is at risk for contrast medium nephropathy
